Glaxo's Shingles Vaccine Shingrix Gets FDA Panel Backing

Date : 14/09/2017 @ 17:10
Source : Dow Jones News
Stock : Glaxosmithkline (GSK)
Quote : 1504.6  -3.0 (-0.20%) @ 23:50
GlaxoSmithKline share price Chart

Glaxo's Shingles Vaccine Shingrix Gets FDA Panel Backing

GlaxoSmithKline (LSE:GSK)
Historical Stock Chart

1 Year : From May 2017 to May 2018

Click Here for more GlaxoSmithKline Charts.

By Razak Musah Baba


LONDON-GlaxoSmithKline PLC's (GSK.LN) shingles vaccine Shingrix, or HZ/su, has been approved for adults aged 50 and over by the U.S. Food and Drug Administration's Advisory Committee.

The pharmaceutical company said Thursday that the FDA's vaccines and related biological products advisory committee, or VRBPAC, voted unanimously that the data support the efficacy and safety of Shingrix for the prevention of herpes zoster or shingles.

The FDA Advisory Committees provide nonbinding recommendations for consideration by the FDA, with the final decision on approval made by the FDA, GSK said.

"Thursday's vote brings us one step closer to approval of Shingrix, which is specifically designed to overcome age-related weakening of the immune system," said Dr. Emmanuel Hanon, senior vice president and head of vaccines research and development.

GSK's shingles candidate vaccine is not currently approved for use anywhere in the world. Regulatory filings in the European Union, Canada, Australia and Japan are underway.


Write to Razak Musah Baba at; Twitter: @Raztweet


(END) Dow Jones Newswires

September 14, 2017 02:55 ET (06:55 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
Your Recent History
Euro vs Au..
US Dollar ..
BHP Bilito..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:au D:20180524 14:05:34